Will NICE recommend Spinraza tomorrow?

Dear Community,

As things stand we still do not know if the decision will be announced tomorrow as to whether Spinraza will be available on the NHS in England, Wales and Northern Ireland. We fully understand that this is an emotional time for all. We live with SMA ourselves and we know the importance of what’s going on from our first hand experience. We are as anxious and scared as any of you. We feel your fear and anticipation. If it was up to us, we all would have had access two years ago!

What we can promise is that we will do everything we can to share updates with you. And we can promise you that our updates are fully accurate and not based on some whisper from a person who has no knowledge of the process. TreatSMA is in the thick of it fighting your corner every single day.

Should there be no update tomorrow we will put a post up in the evening as to how we can push forward as a community for our right to access the only treatment for spinal muscular atrophy.

— The TreatSMA Team

Latest Posts

  • Calling on all the community to ACT NOW to avoid losing treatments!

    Calling on all the community to ACT NOW to avoid losing treatments!

    Currently, there are two approved treatments for SMA: risdiplam and nusinersen. These treatments were initially approved temporarily under Managed Access Agreements while the NHS and NICE gathered data to assess their cost-effectiveness. Now, as these agreements come to an end, both treatments face a crucial review.

    Read more

  • NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    SMA UK are proud to join together with Treat SMA and MDUK to bring you this webinar about NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam. 2024 sees the end of the managed access agreements (MAAs) for the two treatments. An expert committee will gather to assess the new clinical and real-world evidence, along…

    Read more

  • Let the battle begin

    Let the battle begin

    This year the Managed Access Agreement for Spinraza and Risdiplam expires. The MAA was put in place five years ago so the pharmaceutical companies could gather more evidence to resubmit to NICE for approval on the NHS with Biogen extending their MAA by a year.

    Read more